Growth Stock Portfolio: 12 Companies with At Least 30% Annual Growth Rates

Page 6 of 11

6. Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

5-Year Sales Growth: 52.37 %

Market Cap: $41.50 billion

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is among the best stocks added in a growth stock portfolio.

BMO Capital maintained an ‘Outperform’ rating on Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), announcing this on June 24, 2025. The analyst raised its price target on the company’s stock from $300 to $360. BMO Capital attributed this update to a drastic increase in Amvuttra sales for ATTR-CM, according to IQVIA tracking data, after the drug’s approval in March. Furthermore, the analyst cited the continued consistency of the company’s sales trends, reinforcing confidence in its commercial traction.

While short-term skepticism exists regarding the company’s revenue growth, Alnylam Pharmaceuticals, Inc.’s (NASDAQ:ALNY) consistent historical trend of revenue and pipeline growth supports its potential for continued growth.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), a biopharmaceutical company, develops and markets RNAi therapeutics for rare and genetic diseases. The company has demonstrated consistent YoY revenue growth, making it part of the growth stock portfolio.

Page 6 of 11